Cargando…

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide for T2D patients in China based on cost-utili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Shanshan, Su, Xiaorong, Deng, Xun, Wang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220214/ https://www.ncbi.nlm.nih.gov/pubmed/34177604 http://dx.doi.org/10.3389/fphar.2021.701446

Ejemplares similares

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
por: Hu, Shanshan, et al.
Publicado: (2023)

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China
por: Feng, Zhen, et al.
Publicado: (2023)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
por: Zhong, Ping, et al.
Publicado: (2021)

Danhong Injection Price Trend and Its Utilization by Coronary Heart Disease Patients: Evidence From Hospital Records in China
por: Liu, Liming, et al.
Publicado: (2022)

Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
por: Han, Guangxin, et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023)

Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China
por: Li, Zhuoxian, et al.
Publicado: (2021)

Semaglutide for type 2 diabetes
Publicado: (2020)

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
por: de Bruijn, Winnie, et al.
Publicado: (2016)

Antismoking agents do not contribute synergistically to semaglutide’s ability to reduce alcohol intake in rats
por: Aranäs, Cajsa, et al.
Publicado: (2023)

The price and affordability of essential medicines, progress and regional distribution in China: a systematic review
por: Liu, Zheng, et al.
Publicado: (2023)

Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study
por: Yang, Caijun, et al.
Publicado: (2020)

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
por: Gao, Xueqin, et al.
Publicado: (2022)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
por: Guzauskas, Gregory F, et al.
Publicado: (2021)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
por: Narendrula, Aparna, et al.
Publicado: (2023)

Comorbidity in an Older Population with Type-2 Diabetes Mellitus: Identification of the Characteristics and Healthcare Utilization of High-Cost Patients
por: Guerrero-Fernández de Alba, Inmaculada, et al.
Publicado: (2020)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

Impact of the Low-Price Medicine Policy on Medicine Supply in China: An Interrupted Time-Series Analysis
por: Zhao, Mingyue, et al.
Publicado: (2021)

Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
por: Liu, Lei, et al.
Publicado: (2022)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Heterogeneity in Price Elasticity of Medicine Demand in China: Moderate Effect From Economic Incentive and Quality Difference
por: Zhao, Mingyue, et al.
Publicado: (2021)

The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
por: Hu, Shuchen, et al.
Publicado: (2019)

Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study
por: Li, Haiyan, et al.
Publicado: (2022)

The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries
por: Babar, Zaheer-Ud-Din, et al.
Publicado: (2019)

The Crux of the Medicine Prices' Controversy in Pakistan
por: Lee, Kah S., et al.
Publicado: (2017)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States
por: Cui, Jiayu, et al.
Publicado: (2021)

A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES”
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2021)

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017
por: Bai, Lin, et al.
Publicado: (2020)

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
por: Buse, John B, et al.
Publicado: (2023)

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_52lhjd913lijols587n1418opu